The authors observed no clinical evidence of liver or blood-system dysfunction but did not obtain liver-enzyme tests or complete blood counts. Those statements describe different levels of safety observation.
What the report actually documented
The proof-of-concept trial monitored tolerability of CBD/THC preparations and placebo. It reported common adverse events, including sleepiness and decreased appetite, and no treatment-related serious adverse events. In its limitations, the paper stated that liver-enzyme and complete-blood-count tests were not obtained.
A clinical assessment can identify signs or symptoms without supplying the numerical laboratory measurements needed to evaluate some otherwise unapparent abnormalities.
Do not replace missing tests with normal values
The absence of observed clinical dysfunction should not be rewritten as normal measured liver enzymes or blood counts. Equally, absent testing is not proof that an abnormality actually occurred. The evidentiary limit is that this study did not provide those biochemical or hematologic results.
Safety conclusions should name their boundaries
The findings support describing the adverse experiences observed during the study, with its population and duration attached. They do not establish that every relevant laboratory safety marker remained normal or that long-term use is risk-free. Clinical tolerability, laboratory surveillance and rare-event detection require separate evidence.
Related reading: limits of proposed CBD mechanisms.
Research cited
Aran and colleagues (2021). Cannabinoid treatment for autism: a proof-of-concept randomized trial. DOI: 10.1186/s13229-021-00420-2.
Leave a Reply